Shire PLC (NASDAQ:SHPG) issued an update on its FY17 earnings guidance on Friday morning. The company provided EPS guidance of $14.80-15.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $14.92. The company issued revenue guidance of $14.9-15.3 billion, compared to the consensus revenue estimate of $14.97 billion.
Shire PLC (NASDAQ:SHPG) opened at $140.36 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98. The company has a market cap of $42,151.51, a P/E ratio of 9.65, a P/E/G ratio of 0.78 and a beta of 1.60. Shire PLC has a 52 week low of $137.80 and a 52 week high of $192.15.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.64 by $0.17. Shire PLC had a net margin of 10.95% and a return on equity of 14.41%. The business had revenue of $3.70 billion for the quarter. During the same quarter in the previous year, the company posted $3.17 EPS. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year. analysts forecast that Shire PLC will post 15 earnings per share for the current year.
Several equities analysts have issued reports on SHPG shares. Piper Jaffray Companies set a $159.00 price objective on shares of Shire PLC and gave the company a hold rating in a report on Wednesday, July 26th. BidaskClub cut shares of Shire PLC from a sell rating to a strong sell rating in a research report on Wednesday, July 19th. BTIG Research reiterated a buy rating and issued a $242.00 target price on shares of Shire PLC in a research report on Monday, July 17th. Zacks Investment Research lowered shares of Shire PLC from a hold rating to a sell rating in a research note on Monday, July 17th. Finally, Royal Bank Of Canada set a $213.00 price target on shares of Shire PLC and gave the stock a buy rating in a research note on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Shire PLC presently has an average rating of Hold and an average target price of $211.00.
COPYRIGHT VIOLATION WARNING: “Shire PLC (NASDAQ:SHPG) Updates FY17 Earnings Guidance” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/11/12/shire-plc-shpg-updates-fy17-earnings-guidance.html.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.